Live Breaking News & Updates on Ionis Tegsedi

Stay updated with breaking news from Ionis tegsedi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Alnylam's HELIOS-A Trial Meets Secondary Endpoints At 18 Months; Vutrisiran Faces FDA On Apr.14

WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc.'s (ALNY) phase III trial of investigational RNAi therapeutic Vutrisiran in patients with hATTR amyloidosis with polyneuropathy has met all secondary ....

United States , Ionis Tegsedi , Alnylam Onpattro , Alnylam Pharmaceuticals Inc , Neuropathy Impairment Score , Norfolk Quality , Life Questionnaire Diabetic Neuropathy ,